[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
9-Jan-2013

[ | E-mail ] Share Share

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
@jclinicalinvest

Fusion gene contributes to glioblastoma progression

Fusion genes are common chromosomal aberrations in many cancers, and can be used as prognostic markers and drug targets in clinical practice. In this issue of the Journal of Clinical Investigation, researchers led by Matti Annala at Tampere University of Technology in Finland identified a fusion between the FGFR3 and TACC3 genes in human glioblastoma samples. The protein produced by this fusion gene promoted tumor growth and progression in a mouse model of glioblastoma, while increased expression of either of the normal genes did not alter tumor progression. Ivan Babic and Paul Mischel of the University of California, San Diego, explain in the accompanying commentary that it remains unclear how this fusion protein mediates tumorigenesis.

TITLE:
The tumorigenic fusion FGFR3-TACC3 escapes miR-99a regulation in glioblastoma

AUTHOR CONTACT:
Matti Annala
Tampere University of Technology, Tampere, , FIN
Phone: +358415079885; E-mail: matti.annala@tut.fi

View this article at: http://www.jci.org/articles/view/67144?key=b644a26bcc8a516cd41d

ACCOMPANYING COMMENTARY

TITLE:
Multiple functions of a glioblastoma fusion oncogene

AUTHOR CONTACT:
Paul Mischel
UCSD, La Jolla, CA, USA
Phone: (858) 534-6080; Fax: ; E-mail: pmischel@ucsd.edu

View this article at: http://www.jci.org/articles/view/67658?key=0186fce1cd2ddde6082f

###



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.